antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Company profile
Ticker
XNCR
Exchange
Website
CEO
Bassil Dahiyat
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
201622502
XNCR stock data
Latest filings (excl ownership)
8-K
Xencor Appoints Bart Cornelissen as Chief Financial Officer
9 Apr 24
8-K
Regulation FD Disclosure
6 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Entry into a Material Definitive Agreement
15 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Xencor Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Entry into a Material Definitive Agreement
7 Nov 23
8-K
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
26 Oct 23
8-K
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
19 Sep 23
Transcripts
XNCR
Earnings call transcript
2023 Q4
27 Feb 24
XNCR
Earnings call transcript
2023 Q3
7 Nov 23
XNCR
Earnings call transcript
2023 Q2
3 Aug 23
XNCR
Earnings call transcript
2023 Q1
8 May 23
XNCR
Earnings call transcript
2022 Q4
23 Feb 23
XNCR
Earnings call transcript
2022 Q3
8 Nov 22
XNCR
Earnings call transcript
2022 Q2
4 Aug 22
XNCR
Earnings call transcript
2022 Q1
8 May 22
XNCR
Earnings call transcript
2021 Q4
24 Feb 22
XNCR
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Bart Jan Cornelissen
11 Apr 24
3
Bart Jan Cornelissen
11 Apr 24
4
John J Kuch
12 Mar 24
4
Celia Eckert
12 Mar 24
4
John R Desjarlais
12 Mar 24
4
Bassil I Dahiyat
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 53.11 mm | 53.11 mm | 53.11 mm | 53.11 mm | 53.11 mm | 53.11 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.09 mm | 12.69 mm | 9.09 mm | 10.04 mm |
Cash used (since last report) | n/a | n/a | 53.91 mm | 84.53 mm | 60.60 mm | 66.93 mm |
Cash remaining | n/a | n/a | -794.06 k | -31.42 mm | -7.48 mm | -13.82 mm |
Runway (months of cash) | n/a | n/a | -0.1 | -2.5 | -0.8 | -1.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 174 |
Opened positions | 20 |
Closed positions | 24 |
Increased positions | 58 |
Reduced positions | 73 |
13F shares | Current |
---|---|
Total value | 1.25 tn |
Total shares | 63.20 mm |
Total puts | 2.10 k |
Total calls | 500.00 |
Total put/call ratio | 4.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 10.45 mm | $210.56 bn |
Primecap Management | 8.18 mm | $164.91 bn |
Vanguard | 6.65 mm | $134.02 bn |
EcoR1 Capital | 5.28 mm | $106.44 bn |
T. Rowe Price Investment Management | 3.78 mm | $76.15 bn |
FMR | 3.43 mm | $69.15 bn |
T. Rowe Price | 3.18 mm | $64.19 bn |
STT State Street | 2.98 mm | $60.02 bn |
Loomis Sayles & Co L P | 1.51 mm | $30.36 bn |
Armistice Capital | 1.48 mm | $29.78 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Bart Jan Cornelissen | Common Stock | Grant | Acquire A | No | No | 0 | 42,265 | 0.00 | 42,265 |
9 Apr 24 | Bart Jan Cornelissen | Stock Option Common Stock | Grant | Acquire A | No | No | 21.55 | 190,194 | 4.10 mm | 190,194 |
11 Mar 24 | John J Kuch | Common Stock | Sell | Dispose S | No | No | 23.5018 | 849 | 19.95 k | 121,070 |
11 Mar 24 | Celia Eckert | Common Stock | Sell | Dispose S | No | No | 23.5018 | 850 | 19.98 k | 45,465 |
11 Mar 24 | John R Desjarlais | Common Stock | Sell | Dispose S | No | No | 23.5018 | 1,280 | 30.08 k | 186,433 |
News
Analyst Scoreboard: 6 Ratings For Xencor
16 Apr 24
BTIG Maintains Buy on Xencor, Lowers Price Target to $38
16 Apr 24
Piper Sandler Downgrades Xencor to Neutral, Lowers Price Target to $24
28 Feb 24
Unveiling 4 Analyst Insights On Xencor
28 Feb 24
RBC Capital Reiterates Outperform on Xencor, Maintains $32 Price Target
28 Feb 24
Press releases
Xencor Appoints Bart Cornelissen as Chief Financial Officer
9 Apr 24
Xencor to Present at Upcoming Investor Conferences
28 Feb 24
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
20 Feb 24